Tuberculous meningitis: is a 6-month treatment regimen sufficient?
METHODS
The British Thoracic Society and the American Thoracic Society advise 12 months treatment for tuberculous meningitis, with at least isoniazid (H), rifampicin (R) and pyrazinamide (Z).


OBJECTIVE
To establish whether a 6-month treatment regimen for tuberculous meningitis is equally as effective as longer treatment.


METHODS
Medline search for papers published between 1978 and 1999.


METHODS
study populations of patients with tuberculous meningitis in whom the diagnosis was confirmed with clinical, cerebrospinal fluid and epidemiological findings; a treatment regimen with at least HRZ and at least 12 months of follow-up after the completion of treatment.


METHODS
the number of relapses.


RESULTS
There were four 6-month treatment regimens (G6) and seven longer treatment regimens (G>6); 160/197 (81%) patients completed the 6-month treatment regimens, while 577/675 (85%) completed the longer-term regimens. The clinical stage of patients in the G6 group was poorer than in the G>6 group. Relapse occurred in two out of 131 (1.5%) G6 and in 0 out of 591 G>6 patients.


CONCLUSIONS
Although no studies have compared 6-month treatment regimens with longer treatment, it can be concluded on the basis of this literature review that 6-month treatment is sufficient for tuberculous meningitis with fully susceptible mycobacteria.
van Loenhout-Rooyackers
J H
JH
Public Health Office (GGD), Nijmegen, The Netherlands. jloenhout@GGD-Nijmegen.nl
Keyser
A
A
Laheij
R J
RJ
Verbeek
A L
AL
van der Meer
J W
JW
D000328:Adult; D000995:Antitubercular Agents / Q000008:administration & dosage*; D002648:Child; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage; D011718:Pyrazinamide / Q000008:administration & dosage; D012008:Recurrence; D012293:Rifampin / Q000008:administration & dosage; D014390:Tuberculosis, Meningeal / Q000150:complications / Q000188:drug therapy*
D000995:Antitubercular Agents; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin